| 000 | 02043cam a2200361 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030159.0 | ||
| 008 | 100202s2009 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.23.Ph.D.2009.Ne.V | ||
| 100 | 0 | _aNermine Shawki Kamal | |
| 245 | 1 | 0 |
_aValue of bone resorption markers to predict skeletal related events and response to bisphosphonate therapy in patients with bone metastases : _bA prspective randomized study / _cNermine Shawki Kamal ; Supervised Wafaa Elmetenawy , Hamdy Abdelazim , Emad Hamada |
| 246 | 1 | 5 | _aقيمة دلالات اورام تأكل العظام لمعرفة تأثيرها على العظام ومدى استجابتها البيسفوسفونات على علاج مرضى الاورام السرطانية المنتشرة بالعظم |
| 260 |
_aCairo : _bNermine Shawki Kamal , _c2009 |
||
| 300 |
_a215P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology (Clinical) | ||
| 520 | _aThe prospective analysis of urinary N - telopeptides collagen break down products type I (NTX) in patients with metastatic bone disease revealed a positive relation between NTX level and risk of Sketal related events (SREs). Normalization of NTX level at 3 months decreases the rate of serious types of SREs (pathological fractures and cord compression) . Zoledronic acid decreases the rate of one or more SREs by four times in patients with elevated NTX levels compared to no Zoledronic acid | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aBone markers | |
| 653 | 4 | _aMetastatic bone disease | |
| 653 | 4 | _aN - telopeptides | |
| 700 | 0 |
_aEmad Hamada , _eSuperviso |
|
| 700 | 0 |
_aHamdy Abdelazim , _eSupervisor |
|
| 700 | 0 |
_aWafaa Elmetenawy , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 902 | _a1 | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c29283 _d29283 |
||